This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Atherosclerosis Drugs Market

Atherosclerosis Drugs Market

Atherosclerosis Drugs Market By Drug Class (Anti-platelet Medications, Cholesterol Lowering Medications, Beta Blockers, Diuretics, Calcium Channel Blockers), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region - Global Forecast 2020 to 2027

Atherosclerosis Drugs Market
  • Mar-2022
  • List of Tables : 20
  • List of Figures : 99
  • 170 Pages
  • Healthcare

Atherosclerosis Drugs Market: Nanotechnology to Upgrade Quality of Drugs

Competency of nano polymers in imaging further broadens the scope of nanotechnology in the diagnosis of cardiovascular disorders, which makes it the present and the future technology of atherosclerosis drugs.

Nanotechnology is adding a new paradigm in the development of atherosclerosis drugs, owing to its selective drug delivery system that only targets damaged tissues. One such nano polymer, E-selectin-targeting polymer, is used for imaging and drug delivery applications to improve the function of heart muscles.

assessment of atherosclerosis drugs market by drug class

Though technological advancements and demand for drugs are growing at a notable rate, a large number of individuals remain undiagnosed. Low diagnostic rates could hamper the growth potential of the atherosclerosis drugs market during the forecast period (2020-2027).

Avail customized purchase options for your needs

Retail Pharmacies Gaining Prominence in Atherosclerosis Drugs Market

Hospital pharmacies boast of well-stocked inventory with a wide range of prescribed and OTC medications, which makes it convenient for individuals to makes purchases immediately after diagnosis. Numerous government-held hospital pharmacies offer medications at low rates, which further becomes a viable sales opportunity.

key regions in atherosclerosis drugs market

Hospital pharmacies are projected to account for around 46% share in the atherosclerosis drugs market by 2027. However, they could lose market share to retail pharmacies, to some extent, on the back of a large chain of retail pharmacies at key locations, which makes it easy for individuals to refill their drug supplies.

Besides this, in recent times, retail pharmacists are also playing a consultative role, which is likely to influence reliance on retail pharmacies. On account of growing popularity, retail pharmacies are set to register a value equal to US$ 24 Bn by 2027.

An Adaptive Approach to Modern-day Research Needs

Growing Popularity of Generic Drugs – A Concern for North America, an Opportunity for Asia Pacific

Powerful forces at play attributing a high share to the North American atherosclerosis drugs market majorly include large public funding. The American Heart Association actively supports the research & development endeavours of market players, intended towards improving the cardiovascular health of the U.S. population.

Besides this, initiatives taken by the government to upgrade healthcare infrastructure and increase awareness regarding the treatment of numerous disorders are likely to augment diagnostic and drug adoption rates. On the back of numerous favourable drivers, the North America atherosclerosis drugs market is projected to account for 34% market share by 2027.

Though North America holds a leading position in the global atherosclerosis drugs market, increasing sales of generic drugs are impeding the revenue potential of leading players operating in this region. However, the Asia Pacific atherosclerosis drugs market is thriving on the back of growing sales of generic drugs, as a large number of prominent and emerging players are working towards their development.

In addition, Asia Pacific is a price-sensitive region, wherein, affordability of individuals plays a pivotal role in their purchase decisions. Growing preference for generic drugs over branded ones, in parallel with rising awareness regarding atherosclerosis disorders, would create a conducive environment for market growth during the forecast period.

Interested to Procure The Data

Atherosclerosis Drugs Market – Assessment of Key Segments

Authors of this comprehensive study have classified the atherosclerosis drugs market into key segments for an in-depth study of the market. Categorisation of the atherosclerosis drugs market is based on drug class, distribution channel, and region. This detailed study also offers information about the incremental opportunity present in the atherosclerosis drugs market during the forecast period. Key segments considered while studying the atherosclerosis drugs market include:

Drug Class
  • Anti-platelet Medications
  • Cholesterol Lowering Medications
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Beta Blockers
  • Angiotensin-converting Enzyme (ACE) Inhibitors
  • Calcium Channel Blockers
  • Diuretics
  • Others
Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

- FAQs -

Nanotechnology is adding a new paradigm in the development of atherosclerosis drugs, owing to its selective drug delivery system that only targets damaged tissues.
Low diagnostic rates could hamper the growth potential of the atherosclerosis drugs market during the forecast period (2020-2027).

Need an Exclusive Report for your Unique Requirement?

- Related Reports -

Bio-based Polyester Market

Biobased Polyester Market expects US$ 9.6 billion in valuations by 2032 at 16% CAGR. The U.S. bio-ba...

Detox Products Market

Detox Products Market is expected to rise at a 4.6% CAGR by 2031. Sales of detox products through dr...

Demethylase Inhibitor Market

Demethylase Inhibitor Market is set to witness steady growth by 2030 end. Increase in the demand by ...

Antimicrobial Susceptibility Test Market

Antimicrobial Susceptibility Test market research report Segmented By Product (Test & Kits, Culture ...

- Our Clients -

Report Client